45 related articles for article (PubMed ID: 34995690)
1. Discovery of potent antiproliferative agents from selected oxygen heterocycles as EGFR tyrosine kinase inhibitors from the U.S. National Cancer Institute database by in silico screening and bioactivity evaluation.
Jiwacharoenchai N; Saruengkhanphasit R; Niwetmarin W; Seetaha S; Choowongkomon K; Ruchirawat S; Eurtivong C
Bioorg Med Chem Lett; 2022 Feb; 58():128524. PubMed ID: 34995690
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel pyrazole based Urea/Thiourea derivatives as multiple targeting VEGFR-2, EGFR
Fadaly WAA; Nemr MTM; Kahk NM
Bioorg Chem; 2024 Jun; 147():107403. PubMed ID: 38691909
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells.
Zhang Y; Wang Q; Li L; Le Y; Liu L; Yang J; Li Y; Bao G; Yan L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1205-1216. PubMed ID: 34074193
[TBL] [Abstract][Full Text] [Related]
4. Compounds Consisting of Quinazoline, Ibuprofen, and Amino Acids with Cytotoxic and Anti-Inflammatory Effects.
Garduño-Villavicencio LR; Martínez-Ortega U; Ortiz-Sánchez E; Tinajero-Rodríguez JM; Hernández-Luis F
ChemMedChem; 2024 May; 19(10):e202300651. PubMed ID: 38354370
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel EGFR Inhibitors for the Targeted Therapy of Colorectal Cancer Using Pharmacophore Modelling, Docking, Molecular Dynamic Simulation and Biological Activity Prediction.
Krishnan K A; Valavi SG; Joy A
Anticancer Agents Med Chem; 2024; 24(4):263-279. PubMed ID: 38173208
[TBL] [Abstract][Full Text] [Related]
6. New pyrrolidine-carboxamide derivatives as dual antiproliferative EGFR/CDK2 inhibitors.
Frejat FOA; Zhao B; Furaijit N; Wang L; Abou-Zied HA; Fathy HM; Mohamed FAM; Youssif BGM; Wu C
Chem Biol Drug Des; 2024 Jan; 103(1):e14422. PubMed ID: 38230772
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer.
Zheng L; Zhang Y; Mei S; Xie T; Zou Y; Wang Y; Jing H; Xu S; Dramou P; Xu Z; Li J; Zhou Y; Niu MM
J Med Chem; 2024 May; 67(9):7130-7145. PubMed ID: 38630077
[TBL] [Abstract][Full Text] [Related]
8. Development of 1,5-diarylpyrazoles as EGFR/JNK-2 dual inhibitors: design, synthesis, moleecular docking, and bioactivity evaluation.
Soltan OM; Abdel-Aziz SA; Sh Shaykoon M; Osawa K; Narumi A; Abdel-Aziz M; Shoman ME; Konno H
Bioorg Med Chem Lett; 2024 Apr; 102():129673. PubMed ID: 38408511
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 1-phenyl-tetrahydro-β-carboline-based first dual PRMT5/EGFR inhibitors as potential anticancer agents.
Zhang J; Liu X; Sa N; Zhang JH; Cai YS; Wang KM; Xu W; Jiang CS; Zhu KK
Eur J Med Chem; 2024 Apr; 269():116341. PubMed ID: 38518523
[TBL] [Abstract][Full Text] [Related]
10. The anticancer and EGFR-TK/CDK-9 dual inhibitory potentials of new synthetic pyranopyrazole and pyrazolone derivatives: X-ray crystallography,
Musa A; Ihmaid SK; Hughes DL; Said MA; Abulkhair HS; El-Ghorab AH; Abdelgawad MA; Shalaby K; Shaker ME; Alharbi KS; Alotaibi NH; Kays DL; Taylor LJ; Parambi DGT; Alzarea SI; Al-Karmalawy AA; Ahmed HEA; El-Agrody AM
J Biomol Struct Dyn; 2023; 41(21):12411-12425. PubMed ID: 36661285
[TBL] [Abstract][Full Text] [Related]
11. 1,2,3-Triazole-totarol conjugates as potent PIP5K1α lipid kinase inhibitors.
Haidar S; Amesty Á; Oramas-Royo S; Götz C; El-Awaad E; Kaiser J; Bödecker S; Arnold A; Aichele D; Amaro-Luis JM; Estévez-Braun A; Jose J
Bioorg Med Chem; 2024 May; 105():117727. PubMed ID: 38669736
[TBL] [Abstract][Full Text] [Related]
12. Multifaceted approach toward mapping out the anticancer properties of small molecules via in vitro evaluation on melanoma and nonmelanoma skin cancer cells, and in silico target fishing.
Boateng ST; Roy T; Agbo ME; Mahmud MA; Banang-Mbeumi S; Chamcheu RN; Yadav RK; Bramwell M; Pham LK; Dang DD; Jackson KE; Nagalo BM; Hill RA; Efimova T; Fotie J; Chamcheu JC
Chem Biol Drug Des; 2024 Jan; 103(1):e14418. PubMed ID: 38230791
[TBL] [Abstract][Full Text] [Related]
13. Chemical Constituent Profiling of
Abdelhameed RFA; Habib ES; Ibrahim AK; Yamada K; Abdel-Kader MS; Ahmed SA; Ibrahim AK; Badr JM; Nafie MS
Molecules; 2021 Feb; 26(4):. PubMed ID: 33578916
[TBL] [Abstract][Full Text] [Related]
14. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism.
Abourehab MAS; Alqahtani AM; Youssif BGM; Gouda AM
Molecules; 2021 Nov; 26(21):. PubMed ID: 34771085
[TBL] [Abstract][Full Text] [Related]
15. Ligand and structure based hierarchical virtual screening cascade for finding novel epidermal growth factor receptor inhibitors.
Huo D; Sun Z; Wang M; Yan A
Chem Biol Drug Des; 2024 Jan; 103(1):e14375. PubMed ID: 37849030
[TBL] [Abstract][Full Text] [Related]
16. In-Silico Drug discovery approach targeting receptor tyrosine kinase-like orphan receptor 1 for cancer treatment.
Nath O; Singh A; Singh IK
Sci Rep; 2017 Apr; 7(1):1029. PubMed ID: 28432357
[TBL] [Abstract][Full Text] [Related]
17. Discovery of new 5-substituted-indole-2-carboxamides as dual epidermal growth factor receptor (EGFR)/cyclin dependent kinase-2 (CDK2) inhibitors with potent antiproliferative action.
Mohamed FAM; Alakilli SYM; El Azab EF; Baawad FAM; Shaaban EIA; Alrub HA; Hendawy O; Gomaa HAM; Bakr AG; Abdelrahman MH; Trembleau L; Mohammed AF; Youssif BGM
RSC Med Chem; 2023 Apr; 14(4):734-744. PubMed ID: 37122549
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological activity of a fluorescent schweinfurthin analogue.
Kuder CH; Neighbors JD; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2009 Jul; 17(13):4718-23. PubMed ID: 19464190
[TBL] [Abstract][Full Text] [Related]
19. Development of trisubstituted thiophene-3-arboxamide selenide derivatives as novel EGFR kinase inhibitors with cytotoxic activity.
Makhal PN; Sood A; Shaikh AS; Dayare LN; Khatri DK; Rao Kaki V
RSC Med Chem; 2023 Dec; 14(12):2677-2698. PubMed ID: 38107169
[TBL] [Abstract][Full Text] [Related]
20. Structural analysis of cannabinoids against EGFR-TK leads a novel target against EGFR-driven cell lines.
Lamtha T; Tabtimmai L; Songtawee N; Tansakul N; Choowongkomon K
Curr Res Pharmacol Drug Discov; 2022; 3():100132. PubMed ID: 36568260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
